XORTX Therapeutics Inc. (NASDAQ:XRTX) Short Interest Update

Posted by Geri Gentry on Jun 13th, 2026

XORTX Therapeutics Inc. (NASDAQ:XRTX – Get Free Report) was the recipient of a significant decrease in short interest in May. As of May 29th, there was short interest totaling 22,256 shares, a decrease of 58.5% from the May 14th total of 53,649 shares. Currently, 1.4% of the shares of the stock are short sold. Based on an average daily trading volume, of 36,983 shares, the short-interest ratio is currently 0.6 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in XORTX Therapeutics stock. Citadel Advisors LLC raised its stake in XORTX Therapeutics Inc. (NASDAQ:XRTX – Free Report) by 124.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 86,326 shares of the technology company’s stock after acquiring an additional 47,858 shares during the quarter. Citadel Advisors LLC owned approximately 1.24% of XORTX Therapeutics worth $70,000 as of its most recent SEC filing. 0.23% of the stock is currently owned by institutional investors and hedge funds.

XORTX Therapeutics Stock Performance

XORTX Therapeutics stock remained flat at $2.18 during trading hours on Friday. 17,433 shares of the company’s stock were exchanged, compared to its average volume of 29,608. The company has a market cap of $3.77 million, a P/E ratio of -0.83 and a beta of 0.74. XORTX Therapeutics has a 12-month low of $1.73 and a 12-month high of $7.05. The stock has a fifty day moving average price of $2.40 and a 200 day moving average price of $2.50.

XORTX Therapeutics (NASDAQ:XRTX – Get Free Report) last posted its earnings results on Friday, May 15th. The technology company reported ($0.58) EPS for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of XORTX Therapeutics in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

View Our Latest Analysis on XORTX Therapeutics

XORTX Therapeutics Company Profile

(Get Free Report)

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers.